System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Patrick Vermersch is an expert in Neurology at Centre Hospitalier Universitaire de Lille (France). As of October 2026, ScienceLeadR ranks Patrick Vermersch in the top 1% of experts worldwide for Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Autoimmune Diseases. Patrick Vermersch has authored 810 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 9 of them ongoing. SLR score: 2,974 (community average: 125). How the SLR is computed.

LeadR Profile

Patrick Vermersch Centre Hospitalier Universitaire de Lille France
2 974 ScienceLeadR Reputation 2974

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Lille

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 810

Citations

Citations: 36 877 1st author: 100 Last author: 176 Unique author: 25

Main journals

Rev Neurol (Paris) 153
Neurology 135
Mult Scler 63
Mult Scler Relat Disord 41
J Neurol Neurosurg Psychiatry 32

Best Journals

N Engl J Med 9
Lancet Neurol 3
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.
PMID 42552266 — sclerosis, multiple sclerosis, tablets, neurosurgery, cladribine, therapeutics, neurology		J Neurol20260
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.
PMID 42548205 — multiple sclerosis, safety, tablets, cladribine, therapeutics, wounds and injuries, cognition		Mult Scler20261
Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.
PMID 42367807 — sclerosis, multiple sclerosis, aging, brain, immunosenescence, immune system diseases, therapeutics		Front Immunol20260
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.
PMID 42328798 — treatment outcome, sclerosis, multiple sclerosis, safety, magnetic resonance imaging, therapeutics, nervous system diseases		Eur J Neurol20260
Validation and psychometric properties of the Multiple Sclerosis Autonomy Score (MSAS) in a French cohort: The FOCAL-MS 2 study.
PMID 42276022 — sclerosis, multiple sclerosis, psychometrics		Mult Scler Relat Disord20260

Clinical Studies 45

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 33
N/A 7
Phase 4 3
Phase 2 2

By status:

Completed 30
Active not recruiting 5
Terminated 3
Not yet recruiting 2
Recruiting 2
Unknown 2
Suspended 1

By type:

Interventional 40
Observational 5

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 2
multicentricup10 38

Main Topics

Cohort/Consortium Investigators 15

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis
2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis		Phase 3Active not recruiting2024
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis followed by long term treatment with remibrutinib
2023-509372-41-00 — sclerosis, multiple sclerosis, safety, therapeutics		Phase 3Active not recruiting2022
A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and or F Hoffmann La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program
2023-507633-21-01 — sclerosis, multiple sclerosis, therapeutics		Phase 3Not yet recruiting2024
LONG TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS CONSONANCE EXTENSION STUDY
2024-516433-13-00 — safety		Phase 3Recruiting2024
A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis
2023-505974-14-00 — sclerosis, multiple sclerosis, safety		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS